New genetic markers for diagnosis of hepatitis C related hepatocellular carcinoma in Egyptian patients

Journal of Gastrointestinal and Liver Diseases

Volumn 22, Issue 4, 2013, Pages 419-425

  Saad, Yasmin ^a   El Serafy, Magdy ^a   Eldin, Mona S ^a   Abdellatif, Zeinab ^a   Khatab, Hany ^a   Elbaz, Tamer ^a   Elgarem, Hasan ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Gene markers; GPC3; Hepatocellular carcinoma; MK; PEG10; QP C; SERPINI1

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; GLYPICAN 3; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; MESSENGER RNA; MIDKINE; PATERNALLY EXPRESSED 10; SERINE PROTEASE INHIBITOR I1; UBIQUINONE BINDING PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ECHOGRAPHY; EGYPT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENETIC MARKER; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 4; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTIVE VALUE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME;

ADULT; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; EARLY DETECTION OF CANCER; EGYPT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC TESTING; GLYPICANS; HEPATITIS C; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NERVE GROWTH FACTORS; NEUROPEPTIDES; PREDICTIVE VALUE OF TESTS; PROTEINS; RNA, MESSENGER; SERPINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84890498845     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Benvegnu L, Gios M, Boccato S and Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004;53:744-749.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. GLOBOCAN 2008, vo1. 2, Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr,
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-1917.
4. El Zayadi AR, Badran HM, Barakat EM, et al. Hepatocellular carcinoma in Egypt: a single centre study over a decade. World J Gastroenterol 2005;11:5193-5198.
5. Anwar WA, Khaled HM, Amra HA, El-Nezami H, Loffredo CA. Changing pattern of hepatocellular carcinoma (HCC) and its risk factors in Egypt: possibilities for prevention. Mutat Res 2008;659:176-184.
6. Perz JF, Alter MJ. The coming wave of HCV-related liver disease: dilemmas and challenges. J Hepatol 2006:44:441-443.
7. Zhou XD, Tang ZY, Yang BH, et al. Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer 2001;91:1479-1486.
8. Taketa K. α-Fetoprotein: reevaluation in hepatology. Hepatology 1990;12:1420-1432.
9. Jia HL, Ye QH, Qin LX, et al. Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res 2007;13:1133-1139.
10. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-293.
11. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
12. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
13. Schaff Z, Nagy P. Pathology Techniques and Grading Systems in the Diagnosis of HCC. In: Liver cancer. Okuda K, Tabor E. Eds. Churchill Livingstone, New York 1997:111-113.
14. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006;127:679-695.
15. Ring AE, Zabaglo L, Ormerod MG, Smith IE, Dowsett M. Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. Br J Cancer 2005;92:906-912.
16. Smith BM, Slade MJ, English J, et al. Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantitative polymerase chain reaction and immunocytochemical techniques. J Clin Oncol 2000;18:1432-1439.
17. Gertler R, Rosenberg R, Fuehrer K, Dahm M, Nekarda H, Siewert JR. Detection of circulating tumor cells in blood using an optimized density gradient centrifugation. Recent Results Cancer Res 2003;162:149-155.
18. Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol 2012;39:410-433.
19. Yu MW, Chang HC, Chang S, et al. Role of reproductive factors in hepatocellular carcinoma: Impact on Hepatitis B and C-related risk. Hepatology 2003;38:1393-1400.
20. Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
21. Nagasue N, Ogawa Y, Yukaka H, Ohta N, Ito A. Serum levels of estrogens and testosterone in cirrhotic men with and without hepatocellular carcinoma. Gastrenterology 1985;88:768-772.
22. Lehman EM, Soliman AS, Ismail K, et al. Patterns of hepatocellular carcinoma incidence in Egypt from a population based cancer registry. Hepatology Res 2008;38:465-473.
23. Shariff MI, Gomaa AI, Cox IJ, et al. Urinary metabolic biomarkers of hepatocellular carcinoma in an Egyptian population: a validation study. J Proteome Res 2011;10:1828-1836.
24. Di Bisceglie AM, Sterling RK, Chung RT, et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 2005;43:434-441.
25. Farinati F, Marino D, De Giorgio M, et al. Diagnostic and prognostic role of alpha fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 2006;101:524-532.
26. Capurro MI, Xiang YY, Lobe C, Filmus J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 2005;65:6245-6254.
27. Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 2006;12:1175-1181.
28. Hippo Y, Watanabe K, Watanabe A, et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004;64:2418-2423.
29. Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125:89-97.
30. Wang Y, Shen Z, Zhu Z Han R, Huai M. Clinical values of AFP, GPC3 mRNA in peripheral blood for prediction of hepatocellular carcinoma recurrence following OLT: AFP, GPC3 mRNA for prediction of HCC. Hepat Mon 2011;11:195-199.
31. Kandil DH, Cooper K. Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more. Adv Anat Pathol 2009;16:125-129.
32. Yan D, He Q, Chen Y, Wang L, Zhang X. Detection of α-fetoprotein and glypican-3 mRNAs in the peripheral blood of hepatocellular carcinoma patients by using multiple FQ-RT-PCR. J Clin Lab Anal 2011;25:113-117.
33. Youssef MF, El-Sharkawy SL, Abbas NF. Clinical utility of Glypican-3 in hepatocellular carcinoma. Int J Integ Biol 2010;10:41-47.
34. Kadomatsu K, Tomomura M, Muramatsu T. cDNA cloning and sequencing of a new gene intensely expressed in early diTherentiation stages of embryonal carcinoma cells and in mid-gestation period of mouse embryogenesis. Biochem Biophys Res Commun 1988;151:1312-1318.
35. Muramatsu H, Song XJ, Koide N, et al. Enzyme-linked immunoassay for midkine, and its application to evaluation of midkine levels in developing mouse brain and sera from patients with hepatocellular carcinomas. J Biochem 1996;119:1171-1175.
36. Kadomatsu K, Muramatsu T. Midkine and pleiotrophin in neural development and cancer. Cancer Lett 2004;204:127-143.
37. Huang J, Sheng HH, Shen T, et al. Correlation between genomic DNA copy number alterations and transcriptional expression in hepatitis B virus-associated hepatocellular carcinoma. FEBS Lett 2006;580:3571-3581.
38. Ono R, Kobayashi S, Wagatsuma H, et al. A retrotransposon-derived gene, PEG10, is a novel imprinted gene located on human chromosome 7q21. Genomics 2001;73:232-237.
39. Li CM, Margolin AA, Salas M, et al. PEG10 is a c-MYC target gene in cancer cells. Cancer Res 2006;66:665-672.
40. Tsou AP, Chuang YC, Su JY, et al. Overexpression of a novel imprinted gene, PEG10, in human hepatocellular carcinoma and in regenerating mouse livers. J Biomed Sci 2003;10:625-635.
41. Aridome K, Tsutsui J, Takao S, et al. Increased midkine gene expression in human gastrointestinal cancers. Jpn J Cancer Res 1995;86:655-661.
42. Kato M, Shinozawa T, Kato S, Awaya A, Terada T. Increased midkine expression in hepatocellular carcinoma. Arch Pathol Lab Med 2000;124: 848-852.
43. Baker JB, Low DB, Simmer RL, Cunningham DD. Protease-nexin: a cellular component that links thrombin and plasminogen activator and mediates their binding to cells. Cell 1980;21:37-45.
44. Scott RW, Bergman BL, Bajpai A, et al. Protease nexin. Properties and a modified purification procedure. J Biol Chem 1985;260:7029-7034.
45. Gurwitz D, Simon MM, Fruth U, Cunningham DD. Protease nexin-1 complexes and inhibits T cell serine proteinase-1. Biochem Biophys Res Commun 1989;161:300-304.
46. Silverman GA, Bird BL, Carrell RW, et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 2001;276:33293-33296.
47. Chen LM, Zhang X, Chai KX. Regulation of prostasin expression and function in the prostate. Prostate 2004;59:1-12.
48. Myerburg MM, McKenna EE, Luke CJ, Frizzell RA, Kleyman TR, Pilewski JM. Prostasin expression is regulated by airway surface liquid volume and is increased in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2008;294:L932-L941.
49. Bajou K, Noel A, Gerard RD, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998;4:923-928.
50. Bajou K, Peng H, Laug WE, et al. Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis. Cancer Cell 2008;14:324-334.
51. Spano D, Russo R, Di Maso D, et al. Galectin-1 and Its involvement in hepatocellular carcinoma aggressiveness. Mol Med 2010;16:102-115.
52. Suzuki H, Hosokawa Y, Toda H, Nishikimi M, Ozawa T. Cloning and sequencing of a cDNA for human mitochondrial ubiquinone-binding protein of complex III. Biochem Biophys Res Commun 1988;156:987-994.